Bioliberty adds $3.3M to Series A, bringing round to $13.5M
What's the deal? Bioliberty, an Edinburgh-based developer of robotic rehabilitation technology, raised an additional $3.3 million for its Series A, bringing the round to $13.5 million. New US investors TGH VenturesDealroom has a profile for this one. Try Dealroom →, Ballad VenturesDealroom has a profile for this one. Try Dealroom →, and 25M Health backed the extension, alongside Northern Ireland-based Whiterock.
What's the endgame? The company develops Lifelight, an AI-powered robotic glove and software platform that helps stroke survivors and patients with neurological conditions restore upper-body mobility through home-compatible occupational therapy. It embeds the systems across clinical trial centers in the UK and US, using remote biometric monitoring to send real-time data to physical therapists.
Where's the money going? Bioliberty, led by chief executive officer Rowan Armstrong, plans to accelerate its US commercial rollout, expand clinical trials across partner hospital networks, scale engineering and customer success teams, and advance hardware manufacturing.
Why now? The $3.3 million extends a Series A that has grown in stages. TGH Ventures is the venture arm of Tampa General HospitalDealroom has a profile for this one. Try Dealroom →, one of Bioliberty's clinical sites, making the capital as much a commercialization signal as a financing one.
The signal: Investors are backing technology aimed at care delivery and operational efficiency in post-acute care. Basalt HealthDealroom has a profile for this one. Try Dealroom → raised $20 million in September 2026 for software streamlining care transitions, underscoring momentum in the sector that Bioliberty is now pushing into across the US.
Read more: finsmes.com
Image credit: Generated with Gemini
